Novozymes A/S (OTCMKTS:NVZMY) Raised to “Hold” at Zacks Research

Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

Several other research analysts have also issued reports on the company. Rothschild & Co Redburn upgraded Novozymes A/S to a “strong-buy” rating in a research report on Friday, March 27th. Kepler Capital Markets raised Novozymes A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Two analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy”.

Get Novozymes A/S alerts:

View Our Latest Analysis on Novozymes A/S

Novozymes A/S Trading Up 5.0%

NVZMY opened at $59.04 on Monday. The firm has a 50 day simple moving average of $59.38 and a 200 day simple moving average of $60.43. Novozymes A/S has a fifty-two week low of $49.90 and a fifty-two week high of $75.99. The company has a market cap of $24.48 billion, a price-to-earnings ratio of 39.89, a price-to-earnings-growth ratio of 1.05 and a beta of 0.95. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.67 and a quick ratio of 1.03.

Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) last released its earnings results on Tuesday, May 5th. The biotechnology company reported $0.51 EPS for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.31). The business had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.32 billion. Novozymes A/S had a return on equity of 6.52% and a net margin of 14.22%. On average, sell-side analysts anticipate that Novozymes A/S will post 2.43 earnings per share for the current year.

About Novozymes A/S

(Get Free Report)

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).

Further Reading

• Five stocks we like better than Novozymes A/S
• The Bank of Mom and Dad Is Booming—3 Stocks to Watch
• Corning Is Paving AI’s Future With Glass
• Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
• Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer

Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.